News With Merck circling, SpringWorks gets new drug approval Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.
News AZ, MSD's Koselugo is first EU therapy for neurofibromatosis The European Commission has approved AstraZeneca and MSD's Koselugo for a rare genetic condition that causes tumours to develop on the covering of nerve cells, leading to disfigurement and
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.